ATE161171T1 - Schwimmende pulverformige formulierung mit gesteuerter freigabe - Google Patents

Schwimmende pulverformige formulierung mit gesteuerter freigabe

Info

Publication number
ATE161171T1
ATE161171T1 AT92309204T AT92309204T ATE161171T1 AT E161171 T1 ATE161171 T1 AT E161171T1 AT 92309204 T AT92309204 T AT 92309204T AT 92309204 T AT92309204 T AT 92309204T AT E161171 T1 ATE161171 T1 AT E161171T1
Authority
AT
Austria
Prior art keywords
controlled release
powder formulation
release powder
pharmaceutical
weight
Prior art date
Application number
AT92309204T
Other languages
English (en)
Inventor
Andrew Dennis
Peter Timmins
Kevin Lee
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE161171T1 publication Critical patent/ATE161171T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Adjustment And Processing Of Grains (AREA)
  • Disintegrating Or Milling (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
AT92309204T 1991-10-23 1992-10-08 Schwimmende pulverformige formulierung mit gesteuerter freigabe ATE161171T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/781,620 US5169638A (en) 1991-10-23 1991-10-23 Buoyant controlled release powder formulation

Publications (1)

Publication Number Publication Date
ATE161171T1 true ATE161171T1 (de) 1998-01-15

Family

ID=25123359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92309204T ATE161171T1 (de) 1991-10-23 1992-10-08 Schwimmende pulverformige formulierung mit gesteuerter freigabe

Country Status (16)

Country Link
US (1) US5169638A (de)
EP (1) EP0539059B1 (de)
JP (1) JPH05194195A (de)
AT (1) ATE161171T1 (de)
AU (1) AU660193B2 (de)
CA (1) CA2081070C (de)
DE (1) DE69223588T2 (de)
DK (1) DK0539059T3 (de)
ES (1) ES2109986T3 (de)
FI (1) FI108332B (de)
GR (1) GR3026155T3 (de)
HU (1) HU218273B (de)
MX (1) MX9205920A (de)
NO (1) NO304578B1 (de)
NZ (1) NZ244517A (de)
ZA (1) ZA927433B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
AU701042B2 (en) * 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
KR100514264B1 (ko) * 1997-08-26 2005-09-15 아벤티스 파마슈티칼스 인크. 피페리디노알칸올-충혈완화제 조합용 제약 조성물
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EA003101B1 (ru) 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
HK1039456A1 (zh) * 1998-11-02 2002-04-26 Alza Corporation 有效药剂的控制输送
CA2383220C (en) 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
DE60038536T2 (de) * 1999-09-30 2009-06-10 Penwest Pharmaceuticals Co. Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
AU2002220248A1 (en) 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
EP1414458B1 (de) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20030138486A1 (en) * 2001-10-29 2003-07-24 King Pharmaceuticals Research Methods and dosage forms for improving the bioavailability of therapeutic agents
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
WO2003086353A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
RU2234915C2 (ru) * 2002-06-04 2004-08-27 Дж. Б. Кемикалс энд Фармасьютикалс Лтд. Твердая фармацевтическая композиция для перорального введения и способ ее получения
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2512786A1 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
CA2515641A1 (en) * 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
PT1575565E (pt) 2003-08-08 2010-03-03 Biovail Lab Int Srl Comprimido de libertação modificada de cloridrato de bupropiona
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
BRPI0506983A (pt) 2004-01-20 2007-07-03 Allergan Inc composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
EP1722758A1 (de) * 2004-02-11 2006-11-22 Athpharma Limited Chronotherapeutische zusammensetzungen und anwendungsverfahren dafür
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
EP2133071A1 (de) 2008-06-09 2009-12-16 Université de la Méditerranée Verfahren zur Herstellung gastroretentiver Darreichungsformen
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
PT2739270T (pt) * 2011-08-01 2020-04-02 Hb Biotechnologies Corp Cápsulas não digestíveis para a distribuição de materiais absorventes de fluido
KR20150010948A (ko) * 2012-03-23 2015-01-29 파마73, 에스.에이. 피키아 파스토리스 바이오매스로부터 제조된 천연 바이오복합재 분말, 제조방법, 및 부형제로서의 이의 용도
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
US20160244459A1 (en) 2013-05-24 2016-08-25 Rhodes Technologies Opioid ketal compounds and uses thereof
EP3145494A1 (de) 2014-05-21 2017-03-29 Pharma73 S.A. Chitin-glucan-komplex, dessen herstellung und verwendungen
WO2019165298A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
ATE77750T1 (de) * 1984-04-19 1992-07-15 Rhone Poulenc Rorer Int Antisaeurezusammensetzung.
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
PL149493B1 (en) * 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
US4814178A (en) * 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
IE60726B1 (en) * 1988-09-20 1994-08-10 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
NO924104L (no) 1993-04-26
HU218273B (en) 2000-07-28
US5169638A (en) 1992-12-08
HUT63325A (en) 1993-08-30
NO304578B1 (no) 1999-01-18
FI108332B (fi) 2002-01-15
JPH05194195A (ja) 1993-08-03
ES2109986T3 (es) 1998-02-01
DK0539059T3 (da) 1998-01-26
AU2716792A (en) 1993-04-29
FI924831A0 (fi) 1992-10-23
MX9205920A (es) 1993-06-01
CA2081070C (en) 2002-12-24
CA2081070A1 (en) 1993-04-24
DE69223588D1 (de) 1998-01-29
DE69223588T2 (de) 1998-06-25
EP0539059B1 (de) 1997-12-17
NZ244517A (en) 1994-10-26
GR3026155T3 (en) 1998-05-29
ZA927433B (en) 1993-04-07
AU660193B2 (en) 1995-06-15
EP0539059A1 (de) 1993-04-28
NO924104D0 (no) 1992-10-22
HU9203342D0 (en) 1992-12-28
FI924831L (fi) 1993-04-24

Similar Documents

Publication Publication Date Title
ATE161171T1 (de) Schwimmende pulverformige formulierung mit gesteuerter freigabe
HK59681A (en) Pharmaceutical compositions for use in the suppression of gastric reflux
ATE107857T1 (de) Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
CA1217423A (en) Soft capsules
PT1207860E (pt) Formulação de peletes de libertação controlada
ATE64849T1 (de) Formulierung mit langsamer freisetzung.
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
GB1533283A (en) Mixtures for anchoring bone implants
KR890011609A (ko) 구충 분열체를 사용한 포자충증에 대한 생백신
DK187387A (da) Gelatinekapsler og fremgangsmaade til fremstilling heraf
ES2173096T3 (es) Composicion farmaceutica peletizada.
ES510245A0 (es) "un metodo para obtener una preparacion de insulina".
ATE5852T1 (de) Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
IE882898L (en) Solubility modulated drug delivery device
JPS6479109A (en) Floating continuous release therapy composition
KR890003752A (ko) 2-피리미디닐-피페라딘 유도체의 용도
FR2649710B1 (de)
EP0416722A3 (en) Pharmaceutical compositions having differential drug release rate
KR960705562A (ko) 입상 제제(Glanular preparation)
EP1046345A3 (de) Zubereitung zur Verabreichung an Tiere und Fütterungsverfahren
JPS5534058A (en) Immobilization of bioactive substance to powdery carrier

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee